Glaxo To Take $2.4 Billion Hit Over Avandia Cases
More Info: Defective Drugs
Even for a flush drugmaker like GlaxoSmithKline, $2.4 billion dollars is a lot of money to wipe off the books in a single quarter.
Yet, just hours after a panel of U.S. experts voted in favor of keeping Glaxo’s diabetes pill Avandia on the market, despite known heart risks, that’s what the drugmaker said it would do in its second quarter.
All that money wil go to cover the cost of a bunch of legal problems, including the settlement of lawsuits over harm allegedly linked to Avandia.
The company said “the substantial majority of the product liability cases relating to Avandia have now been settled.” Glaxo hasn’t disclosed how much money that involves. But Bloomberg reported the company has already agreed to pay about $460 million to put those cases to rest.
It could have been worse. Before the meeting of experts advising the Food and Drug Administration on Avandia concluded Tuesday, some analysts figured the Avandia costs could run as high as $6 billion, Reuters reported.
See the full, original post here: https://www.npr.org/sections/health-shots/2010/07/15/128534637/glaxo-takes-2-4-billion-charge-to-cover-avandia-cases
TriMark Legal Funding was founded in 2003 and is one of America's original lawsuit funding companies. TriMark provides pre settlement loans and post settlement loans to injured plaintiffs who are involved in personal injury lawsuits, employment litigation, work injury accidents and workers compensation lawsuits, mass tort litigation, and multidistrict litigation. We also provide post settlement funding to attorneys and loans to law firms.
|Other Mass Tort Litigation Funding||Other Multidistrict Litigation Funding|
Click here to see the original article.